Form 4: Provectus CEO Converts Note to Preferred Stock

Provectus Biopharmaceuticals CEO Edward Pershing converted an $50,000 unsecured promissory note into 18,880 shares of Series D-1 Convertible Preferred Stock.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted an 8% unsecured convertible promissory note (the "2024 Note") into Series D-1 Convertible Preferred Stock.
• The 2024 Note, with an outstanding principal and interest of $50,000, automatically converted into 18,880 shares of Series D-1 Preferred Stock at a price of $2.862 per share.
• The conversion occurred on August 8, 2025, which was twelve months after the 2024 Note's issue date, as per its terms.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.
• Following the transaction, Edward Pershing beneficially owns 1,370,000 shares of Series D-1 Convertible Preferred Stock and 2,314,607 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The filing reports a pre-planned, automatic conversion of a convertible note held by the CEO into preferred stock, which is a neutral event in terms of immediate sentiment, representing a debt-to-equity conversion.

Positives

• The conversion of the promissory note into preferred stock reduces the company's outstanding debt, potentially improving its balance sheet structure.

Negatives

• The conversion of preferred stock into common stock in the future could lead to dilution for existing common shareholders.

Risks

• Potential future dilution of common stock due to the automatic conversion of Series D-1 Convertible Preferred Stock into common shares by June 20, 2026, or earlier.

Future Outlook

The Series D-1 Convertible Preferred Stock held by the reporting person will automatically convert into Common Stock on June 20, 2026, unless an earlier voluntary conversion occurs.

Industry Context

The conversion of convertible notes into equity is a common financing strategy for biotechnology companies, particularly those in development stages, to manage debt and strengthen their equity base. This transaction reflects a pre-existing financing arrangement coming to fruition.

Related Party Transactions

• Edward Pershing, who serves as CEO and Director of Provectus Biopharmaceuticals, Inc., converted an 8% unsecured convertible promissory note he held into Series D-1 Convertible Preferred Stock of the company. This constitutes a transaction between a key executive/director and the company.

Stakeholder Impact

• Existing common shareholders may experience future dilution when the Series D-1 Convertible Preferred Stock converts into common stock, increasing the total number of outstanding shares.

Next Steps

• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock by June 20, 2026, unless earlier converted.

Key Dates

Keywords

Provectus Biopharmaceuticals, PVCT, SEC Form 4, Insider Transaction, Convertible Note, Preferred Stock, Edward Pershing, CEO, Debt Conversion, Equity Dilution